Effect | None |
Trial Design | Double blind |
Trial Length | 1-6 months |
Number of Subjects | 20 |
Sex | Both Genders |
Age Range | 18-29, 30-44, 45-64 |
Body Types | Average |
The addition of 400 µg chromium (as picolinate) to antipsycotic therapy in a small sample of schizophrenic persons over three months failed to significantly influence symptoms of schizophrenia relative to control as assessed by PANSS and HAM-D rating scales.